Pediatric AIDS-Therapeutic Successes Built on a Foundation of Pediatric Clinical Pharmacology with Pharmacokinetic-Pharmacodynamic Modeling.
作者信息
Capparelli Edmund V
机构信息
Departments of Pediatrics and Clinical Pharmacy (EVC), University of California-San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Science, La Jolla, CA.
出版信息
J Pediatr Pharmacol Ther. 2022;27(6):482-489. doi: 10.5863/1551-6776-27.6.482. Epub 2022 Aug 19.
Abstract
摘要
相似文献
1
Pediatric AIDS-Therapeutic Successes Built on a Foundation of Pediatric Clinical Pharmacology with Pharmacokinetic-Pharmacodynamic Modeling.基于儿科临床药理学及药代动力学-药效学模型基础之上的儿科艾滋病治疗成功案例。
J Pediatr Pharmacol Ther. 2022;27(6):482-489. doi: 10.5863/1551-6776-27.6.482. Epub 2022 Aug 19.
2
Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.种族差异再探讨：给药方案和剂型对药代动力学和药效学的影响
Clin Pharmacokinet. 2006;45(10):957-64. doi: 10.2165/00003088-200645100-00001.
3
Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology.药物代谢动力学建模与模拟对儿科临床药理学至关重要。
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S73-S85. doi: 10.1002/jcph.1316.
4
Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.利用效应室浓度达峰时间结合药代动力学和药效学。
Anesthesiology. 2003 Aug;99(2):324-33. doi: 10.1097/00000542-200308000-00014.
5
Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.定量临床药理学在儿科药物批准和标签中的作用。
Drug Metab Dispos. 2016 Jul;44(7):924-33. doi: 10.1124/dmd.116.069559. Epub 2016 Apr 14.
6
State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.儿科药物开发中基于生理的药代动力学建模的最新技术综述。
Clin Pharmacokinet. 2019 Jan;58(1):1-13. doi: 10.1007/s40262-018-0677-y.
7
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.依曲韦林在PIANO研究中感染HIV-1、有治疗经验的儿童和青少年中的药代动力学及药代动力学/药效学关系
J Clin Pharmacol. 2016 Nov;56(11):1395-1405. doi: 10.1002/jcph.746.
8
Improving predictive modeling in pediatric drug development: pharmacokinetics, pharmacodynamics, and mechanistic modeling.改善儿科药物研发中的预测模型：药代动力学、药效学和机制模型
Ann N Y Acad Sci. 2005 Aug;1053:505-18. doi: 10.1111/j.1749-6632.2005.tb00061.x.
9
Pharmacokinetics and population pharmacokinetics in pediatric oncology.儿科肿瘤的药代动力学和群体药代动力学。
Pediatr Blood Cancer. 2020 Apr;67(4):e28132. doi: 10.1002/pbc.28132. Epub 2019 Dec 25.
10
Pharmacokinetic/pharmacodynamic modeling in drug research and development.药物研发中的药代动力学/药效学建模
J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1399-418.
本文引用的文献
1
Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children.儿童患者中静脉注射 10-1074 和 VRC01LS 的安全性和药代动力学。
J Acquir Immune Defic Syndr. 2022 Oct 1;91(2):182-188. doi: 10.1097/QAI.0000000000003033.
2
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.CYP2B6 基因型、结核病治疗和剂型对 40 月龄以下婴儿和儿童依非韦伦药代动力学的影响。
AIDS. 2022 Mar 15;36(4):525-532. doi: 10.1097/QAD.0000000000003141.
3
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.新生儿中阿巴卡韦/拉米夫定/洛匹那韦/利托那韦固定剂量颗粒制剂（4-in-1）的药代动力学和安全性：PETITE 研究。
J Acquir Immune Defic Syndr. 2022 Mar 1;89(3):324-331. doi: 10.1097/QAI.0000000000002871.
4
Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation.利用群体药代动力学建模与模拟优化新生儿中多替拉韦的起始治疗。
J Acquir Immune Defic Syndr. 2022 Jan 1;89(1):108-114. doi: 10.1097/QAI.0000000000002830.
5
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.在 HIV-1 暴露的新生儿中长效广泛中和人免疫缺陷病毒 1 型（HIV-1）单克隆抗体 VRC01LS 的安全性、耐受性和药代动力学。
J Infect Dis. 2021 Dec 1;224(11):1916-1924. doi: 10.1093/infdis/jiab229.
6
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.早期基于奈韦拉平的抗逆转录病毒疗法在围生期 HIV 感染高危新生儿中的药代动力学和安全性：一项 1/2 期概念验证研究。
Lancet HIV. 2021 Mar;8(3):e149-e157. doi: 10.1016/S2352-3018(20)30274-5. Epub 2020 Nov 23.
7
Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach.使用群体药代动力学方法对新生儿进行VRC01的模型指导开发。
Clin Pharmacol Ther. 2021 Jan;109(1):184-192. doi: 10.1002/cpt.2026. Epub 2020 Oct 3.
8
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.多替拉韦与依非韦伦在晚期妊娠开始抗 HIV 治疗的女性中的应用（DolPHIN-2）：一项开放标签、随机对照试验。
Lancet HIV. 2020 May;7(5):e332-e339. doi: 10.1016/S2352-3018(20)30050-3.
9
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.拉替拉韦与依非韦伦在 HIV 感染的抗逆转录病毒初治孕妇中的应用（NICHD P1081）：一项开放标签、随机、对照、4 期临床试验。
Lancet HIV. 2020 May;7(5):e322-e331. doi: 10.1016/S2352-3018(20)30038-2.
10
Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.广泛中和人免疫缺陷病毒（HIV）-1 单克隆抗体 VRC01 在 HIV 暴露新生儿中的安全性、耐受性和药代动力学。
J Infect Dis. 2020 Jul 23;222(4):628-636. doi: 10.1093/infdis/jiz532.
Zotero 插件